MEI Pharma (NASDAQ:MEIP) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Posted by Lisa Pomrenke on Feb 11th, 2025

MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.91 and traded as low as $2.67. MEI Pharma shares last traded at $2.77, with a volume of 5,441 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of MEI Pharma in a research note on Tuesday. They issued a “buy” rating on the stock.

Get Our Latest Stock Report on MEIP

MEI Pharma Price Performance

The company has a market cap of $18.45 million, a P/E ratio of -0.40 and a beta of 0.79. The business’s 50 day moving average price is $2.68 and its 200-day moving average price is $2.91.

MEI Pharma (NASDAQ:MEIP – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.20) earnings per share for the quarter. As a group, research analysts forecast that MEI Pharma, Inc. will post -5.1 EPS for the current year.

Institutional Trading of MEI Pharma

A hedge fund recently bought a new stake in MEI Pharma stock. Corsair Capital Management L.P. acquired a new stake in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 24,370 shares of the company’s stock, valued at approximately $69,000. Corsair Capital Management L.P. owned approximately 0.37% of MEI Pharma at the end of the most recent quarter. 52.38% of the stock is currently owned by institutional investors.

MEI Pharma Company Profile

(Get Free Report)

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.